Merck & Co., Inc.MRKNYSE

Overview Intelligence Charts News Fundamentals Key Metrics Financials Growth Insiders

Latest News

globenewswire.com

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212, the Company's novel oral bio-conjugated therapy and will host a conference call to discuss the data today at 9:00am ET.

seekingalpha.com

Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference Transcript

benzinga.com

AI-Powered Tempus Inks New Multi-Year Merck Deal

Tempus AI Inc. (NASDAQ: TEM) on Tuesday inked a strategic collaboration agreement with Merck & Co. Inc. (NYSE: MRK) aimed at accelerating AI-driven precision medicine.

247wallst.com

Most Retirees Overlook These Dow Dividend Stocks — They Pay More Than You'd Expect

The Dow Jones Industrial Average, commonly just called the Dow Jones or the Dow, includes 30 giant publicly listed companies with U.S.

zacks.com

Merck's Keytruda Drives its 2025 Revenue Surge: What's Ahead?

Merck MRK has a strong foothold in the oncology market, primarily supported by its biggest revenue driver, Keytruda. The blockbuster PD-1 inhibitor accounts for around 55% of the company's pharmaceutical sales and has played an instrumental role in driving Merck's steady revenue growth over the past few years.

zacks.com

Merck (MRK) Stock Dips While Market Gains: Key Facts

In the latest trading session, Merck (MRK) closed at $121.41, marking a -1.95% move from the previous day.

zacks.com

Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

defenseworld.net

Becker Capital Management Inc. Has $25.12 Million Stock Position in Merck & Co., Inc. $MRK

Becker Capital Management Inc. lessened its stake in Merck and Co., Inc. (NYSE: MRK) by 2.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 296,427 shares of the company's stock after selling 7,498 shares during the quarter. Becker

defenseworld.net

Bright Futures Wealth Management LLC. Buys Shares of 5,628 Merck & Co., Inc. $MRK

Bright Futures Wealth Management LLC. purchased a new position in shares of Merck and Co., Inc. (NYSE: MRK) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 5,628 shares of the company's stock, valued at approximately $472,000. Other hedge funds and other institutional

defenseworld.net

Davis R M Inc. Lowers Stake in Merck & Co., Inc. $MRK

Davis R M Inc. lessened its stake in Merck and Co., Inc. (NYSE: MRK) by 32.7% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,404 shares of the company's stock after selling 12,850 shares during the period. Davis R M Inc.'s

defenseworld.net

111 Capital Has $1.71 Million Holdings in Merck & Co., Inc. $MRK

111 Capital increased its position in Merck and Co., Inc. (NYSE: MRK) by 48.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 20,391 shares of the company's stock after buying an additional 6,685 shares during the period. 111 Capital's holdings in Merck and

defenseworld.net

Merck & Co., Inc. $MRK Shares Sold by Diversify Wealth Management LLC

Diversify Wealth Management LLC lowered its position in shares of Merck and Co., Inc. (NYSE: MRK) by 63.9% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 13,731 shares of the company's stock after selling 24,300 shares during the period. Diversify Wealth Management LLC's holdings in

businesswire.com

KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients With Earlier-Stage RCC.

businesswire.com

WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--WELIREG Plus LENVIMA Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated RCC Patients.

defenseworld.net

Merck & Co., Inc. $MRK Shares Purchased by American Century Companies Inc.

American Century Companies Inc. increased its stake in shares of Merck and Co., Inc. (NYSE: MRK) by 20.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,559,640 shares of the company's stock after buying an additional 787,181 shares

defenseworld.net

Banco Santander S.A. Reduces Stake in Merck & Co., Inc. $MRK

Banco Santander S.A. lessened its position in shares of Merck and Co., Inc. (NYSE: MRK) by 58.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 155,068 shares of the company's stock after selling 216,463 shares during the quarter. Banco Santander

defenseworld.net

Artisan Partners Limited Partnership Increases Position in Merck & Co., Inc. $MRK

Artisan Partners Limited Partnership raised its position in shares of Merck and Co., Inc. (NYSE: MRK) by 2.6% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,334,597 shares of the company's stock after buying an additional 33,849 shares during

reuters.com

Merck to lay off around 150 employees at US site amid slump in Gardasil sales

Merck will lay off about 150 employees across its facility in North Carolina that manufactures its human papillomavirus vaccine, Gardasil, according to a notice filed in the state's database this week.

investors.com

Merck Stock, Up 13% In 2026, Ticks Another Box. Is It Now A Buy?

Merck stock ticked another box Friday after the firm said its Keytruda-containing regimen improved outcomes for ovarian cancer patients.

businesswire.com

KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the final analysis of the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, showing that KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab significantly improved overall survival (OS), a key secondary endpoint, for patients with platinum-resistant recurrent ovarian cancer rega.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance